Skip to main content
EnglishEN
European Commission logo print header

Immune Niches for Cancer ImmunoTherapy Enhancement

Project description

DEENESFRITPL

An engineered niche for the education of anti-tumour T cells

Over the years, a number of immunotherapy approaches have been developed to treat cancer, including immune checkpoint inhibitors and engineered T cells. Despite their excellent efficacy against haematological malignancies, their therapeutic impact on solid tumours has proved limited. The working hypothesis of the EU-funded INCITE project is that the clinical failure of immunotherapy is based on the fact that we do not educate the right type of anti-tumour T cells. Therefore, INCITE scientists will engineer a functional immune niche for the selection and expansion of tumour-rejecting T cells. Generating the fittest anti-tumour T cells for adoptive therapy will significantly improve cancer treatment.

Objective

Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer by checkpoint inhibitors, vaccines or adoptive T cell therapy is coming of age and has the potential to cure cancer, but is still hampered by some major limitations. For instance, Adoptive Cell Therapy (ACT) with unmanipulated or engineered T cells (TCR-transgenic and CAR-T cells) has indeed demonstrated success in the treatment of patients affected by leukemias, but is much less effective against lymphomas and solid tumors. One likely explanation is that we do not educate the right type of anti-tumor T cells. The T cells considered to be the gold standard for tumor therapy have stem cell memory features, but the proper and safe way to generate these fit T cells for clinical purposes is still an unresolved matter. Here we propose an advanced transformative technology termed INCITE, utilizing a novel high-resolution 3D microfabrication technology to engineer a specially tailored microenvironment that will be inhabited by cells central for T cells education in order to generate the fittest anti-tumor T cells for advanced adoptive T cell therapy. INCITE will bring together a transdisciplinary consortium capable of developing this innovative platform by combining state-of-the-art 3D printing, computer modeling, bioengineering, bioinformatics, immunology, developmental and cancer biology approaches, toward the development of a functional immune niche for selection and expansion of tumor-rejecting T cells. The INCITE platform will revolutionize the treatment of cancer patients with ACT, with a profound impact on the quality of life and well-being of millions of people.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-FETOPEN-2018-2020

See other projects for this call

Sub call

H2020-FETOPEN-2018-2019-2020-01

Funding Scheme

RIA - Research and Innovation action

Coordinator

NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
Net EU contribution
€ 710 000,00
Address
HOGSKOLERINGEN 1
7491 Trondheim
Norway

See on map
Region
Norge Trøndelag Trøndelag
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 710 000,00

Participants (7)

Share this page

Download

Last update: 27 December 2023

My Booklet

Permalink: https://cordis.europa.eu/project/id/964955

European Union, 2024